Larazotide
updated
Larazotide acetate (AT-1001) is an eight-amino-acid oral peptide designed to tighten the gut lining's junctions, studied for celiac disease, unapproved in the US. It is promoted for leaky gut and as a celiac cure, though no registered trial targets leaky gut. In 342 adults with celiac symptoms despite a gluten-free diet, the lowest dose eased symptoms while two higher doses did not, and the pivotal 307-person phase 3 was stopped after an interim analysis without posted results. Graded D for that mixed, unconfirmed record, with a finished Long COVID study also unreported.
Oral tight-junction regulator peptide
- Eight-amino-acid peptide
- Also called AT-1001 and INN-202
- Studied in an enteric-coated oral formulation
- No approved U.S. prescribing label found
What did the published celiac trial actually find?
In 342 adults with celiac disease who still had symptoms despite at least 12 months on a gluten-free diet, 0.5 mg larazotide acetate three times daily improved the average on-treatment gastrointestinal symptom score versus placebo. The primary analysis gave P = 0.022, with P = 0.005 in the repeated-measures model.
The treatment lasted 12 weeks after a 4-week placebo run-in. The drug was an adjunct to the participants' existing gluten-free diet, not a replacement for it.
source: Phase 2b celiac trial · 0.5 mg signal, Leffler et al., Gastroenterology, 2015
Did the trial show a consistent dose response?
The 1 mg and 2 mg three-times-daily groups were no different from placebo on any endpoint. Only the lowest tested dose met the primary endpoint, so the study did not show a conventional increasing dose response.
Exploratory results at 0.5 mg included 26% fewer symptomatic days and 31% more improved-symptom days. Those were secondary findings from the same trial, not independent replications.
Why was the pivotal CeDLara trial terminated?
CeDLara randomized 307 participants before the sponsor terminated it. The sponsor's SEC filing says an independent interim analysis indicated that the additional sample needed for a significant placebo difference would be too large to support continuation. The registry has no posted results.
The registry's public reason says only "Trial terminated by Sponsor." The SEC filing supplies the interim-analysis context. Neither source provides an efficacy estimate for the 307 participants.
source: CeDLara · terminated with no results, ClinicalTrials.gov, NCT03569007
source: Sponsor filing · CeDLara interim decision, 9 Meters Biopharma, Form 10-K for 2022
What is the current status of the Long COVID trial?
NCT05747534 is completed, with 107 actual participants and a June 18, 2026 completion date. It tested larazotide against placebo in people ages 7 through 50, but the registry posts no results.
The research schedule was 250 or 500 micrograms by body weight, taken four times daily for 21 days, with adverse events and symptom resolution assessed over 8 weeks. That is a monitored study protocol, not routine-use guidance.
source: NCT05747534 · completed, no results, ClinicalTrials.gov, NCT05747534
How is larazotide supposed to work, and does it enter the blood?
The studied enteric-coated formulation was designed to release an octapeptide in the small intestine and regulate epithelial tight junctions. The proposed pathway involves zonulin signaling and cytoskeletal junction proteins, but the precise receptor-level mechanism remains unsettled. Some early celiac trials listed intestinal permeability as an outcome, but the published phase 2b efficacy result is a symptom score in 342 adults with celiac disease. No ClinicalTrials.gov record for larazotide lists “leaky gut” as its condition: the registered studies cover celiac disease, Long COVID, a COVID-19-related inflammatory syndrome in children and healthy volunteers (search of October 24, 2026).
"Gut restricted" describes the low systemic exposure of the studied formulation. It does not establish zero absorption or equivalence to a different oral product.
source: Mechanism review · gut-targeted formulation, Slifer and Blikslager, American Journal of Physiology Gastrointestinal and Liver Physiology, 2021
source: Sponsor filing · CeDLara interim decision
source: Phase 2b celiac trial · 0.5 mg signal
source: Registry · no leaky-gut study, ClinicalTrials.gov search run on October 24, 2026 for larazotide OR AT1001 OR AT-1001 OR INN-202: 34 records, of which the larazotide studies list celiac disease, Long COVID (NCT05747534), COVID-19-related MIS-C (NCT05022303) or healthy volunteers (NCT00386490) as conditions; the rest are migalastat studies that share the AT1001 code. NCT00386165, NCT00362856 and NCT00492960 list intestinal permeability outcomes.
Is larazotide an FDA-approved or commercially established medicine?
The cited FDA records list no approved larazotide product or prescribing label. The celiac program did not reach approval, and the completed Long COVID trial has not posted results.
None of the investigational studies, emergency IND uses, patents, or formulation records provides a marketing authorization or prescribing label.
source: FDA records · no approved label, Drugs@FDA and FDA labeling records for larazotide and its aliases.
How complete is the record of larazotide side effects and interactions?
In the 12-week celiac phase 2b study, overall safety was comparable with placebo; gastrointestinal disorders were the most frequent treatment-emergent class and no serious adverse event was judged drug related. That short trial cannot define long-term, pediatric, pregnancy, interaction, or rare-harm risks.
source: Phase 2b celiac trial · 0.5 mg signal
source: FDA records · no approved label
Studies and sources
Phase 2b celiac trial · 0.5 mg signal
Randomized controlled trial
Leffler et al., Gastroenterology, 2015
Among 342 adults with persistent celiac symptoms on a gluten-free diet, 0.5 mg three times daily met the gastrointestinal symptom primary endpoint versus placebo. The 1 mg and 2 mg groups did not differ from placebo on any endpoint, and short-term safety was comparable.
- Primary analysis at 0.5 mg: P = 0.022
- Repeated-measures analysis at 0.5 mg: P = 0.005
- Higher doses did not separate
- Participants / model
- Adults with celiac disease, persistent symptoms, and at least 12 months on a gluten-free diet
- Treatment
- Larazotide acetate 0.5, 1, or 2 mg three times daily versus placebo; gluten-free diet continued
- Follow-up
- 4-week placebo run-in, 12-week treatment, 4-week run-out
- Study design
- Multicenter randomized double-blind placebo-controlled phase 2b trial
The positive dose was not supported by the two higher-dose arms and has not been confirmed in a successful pivotal trial.
Read the original sourceCeDLara · terminated with no results
Clinical trial registry record
ClinicalTrials.gov, NCT03569007
The phase 3 celiac study lists 307 actual participants, terminated status, a July 21, 2022 completion date, and no posted results. The public reason is "Trial terminated by Sponsor."
- Participants / model
- Adults with celiac disease and persistent symptoms despite a gluten-free diet
- Treatment
- Enteric-coated larazotide 0.25 mg or 0.50 mg three times daily versus placebo
- Follow-up
- Terminated; actual completion July 21, 2022
- Study design
- Randomized triple-masked placebo-controlled phase 3 trial
- Funding
- 9 Meters Biopharma
The registry does not post outcome data and gives no numerical futility boundary.
Read the original sourceSponsor filing · CeDLara interim decision
SEC filing
9 Meters Biopharma, Form 10-K for 2022
The company reported that an independent interim analysis found the additional number of participants needed to reach a significant placebo difference would be too large to support continuation, after which it discontinued celiac development.
- The filing also describes the enteric-coated multiparticulate oral formulation.
- Participants / model
- CeDLara celiac development program
- Treatment
- Larazotide acetate
- Follow-up
- Decision disclosed for June 2022
- Study design
- Sponsor regulatory and financial disclosure
- Funding
- Company filing
This explains the sponsor's decision but is not a substitute for participant-level or posted trial results.
Read the original sourceNCT05747534 · completed, no results
Clinical trial registry record
ClinicalTrials.gov, NCT05747534
The randomized phase 2 study is completed with 107 actual participants and no posted results. It tested 21 days of weight-banded larazotide or placebo and assessed adverse events and symptom resolution over 8 weeks.
- Actual completion June 18, 2026
- The registry posts no results.
- Participants / model
- Children, adolescents, and adults ages 7 through 50 with Long COVID
- Treatment
- Oral larazotide acetate 250 micrograms below 25 kg or 500 micrograms at or above 25 kg, four times daily, versus placebo
- Follow-up
- 21 days treatment; 8-week primary assessment
- Study design
- Randomized quadruple-masked placebo-controlled phase 2 trial
- Funding
- Massachusetts General Hospital
Completion does not establish benefit or safety while the result tables remain absent.
Read the original sourceMechanism review · gut-targeted formulation
Peer-reviewed mechanistic review
Slifer and Blikslager, American Journal of Physiology Gastrointestinal and Liver Physiology, 2021
The review describes larazotide as an eight-amino-acid, intestine-targeted tight-junction regulator and summarizes proposed zonulin, cytoskeletal, and myosin-light-chain-kinase pathways. It also notes unresolved details in the proposed receptor pathway.
- Participants / model
- Cell, animal, formulation, and clinical literature
- Treatment
- Larazotide acetate
- Follow-up
- Literature through publication
- Study design
- Narrative mechanistic review
This 2021 mechanism review predates the 2022 CeDLara termination and provides no current approval or clinical efficacy result.
Read the original sourceFDA records · no approved label
FDA drug records
Drugs@FDA and FDA labeling records for larazotide and its aliases.
The cited U.S. FDA records list no approved product or prescribing label under larazotide, larazotide acetate, AT-1001, or INN-202.
- Participants / model
- United States marketing authorizations
- Treatment
- Larazotide aliases
The cited databases cover U.S. drug approval; they do not establish commercial status elsewhere.
Read the original sourceRegistry · no leaky-gut study
Trial registry record
ClinicalTrials.gov search run on October 24, 2026 for larazotide OR AT1001 OR AT-1001 OR INN-202: 34 records, of which the larazotide studies list celiac disease, Long COVID (NCT05747534), COVID-19-related MIS-C (NCT05022303) or healthy volunteers (NCT00386490) as conditions; the rest are migalastat studies that share the AT1001 code. NCT00386165, NCT00362856 and NCT00492960 list intestinal permeability outcomes.
No larazotide record lists leaky gut as a condition.
Why is Larazotide in D tier?
D reflects a mixed, unconfirmed clinical record. One dose met the celiac symptom endpoint, higher doses did not, the pivotal study stopped without results, and the completed Long COVID study has not reported outcomes.
how tiers are graded: methodology · every cited source · about reptides.
Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.